ODZ10117
ODZ10117 is a STAT3 and NLRP3 inhibitor with a human STAT3 SH2 domain IC50 of 7.5 μM. ODZ10117 binds to the STAT3 SH2 domain, suppressing tyrosine phosphorylation, dimerization, nuclear translocation, and transcriptional activity. ODZ10117 binds to NLRP3, impairs NEK7 interaction, prevents inflammasome formation, and inhibits caspase-1 and IL-1β cleavage.ODZ10117 reduces MSU (HY-B2130A)-induced IL-1β release, lowers LPS (HY-D1056)-induced sepsis mortality, and exhibits anti-inflammatory effects. ODZ10117 induces apoptosis, suppresses breast cancer cell migration and invasion, reduces tumor growth and lung metastasis, and extends survival in breast cancer models. ODZ10117 can be used for the research of Monosodium urate (HY-B2130A)-induced peritonitis, LPS-induced sepsis, breast cancer, glioblastoma, and Alzheimer's disease.
For research use only. We do not sell to patients.
- CAS No.: 1632152-27-2
- Formula: C10H5Cl5N2O2
- Molecular Weight:362.42
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
|
NLRP3 |
STAT3 7.5 μM (IC50) |
In Vitro
ODZ10117 (5-40 μM; 6 h) exhibits no significant cytotoxicity on mouse bone marrow-derived macrophages at concentrations up to 40 μM following 6-hour incubation[1].
ODZ10117 (5-20 μM; 1 h pretreatment) dose-dependently inhibits NLRP3 inflammasome-mediated IL-1β release and pyroptosis in LPS-primed mouse bone marrow-derived macrophages treated with ATP, nigericin, silica crystals, or imiquimod, with maximal inhibition at 20 μM[1].
ODZ10117 (5-20 μM; 1 h pretreatment) inhibits NLRP3 inflammasome activation in LPS-primed mouse bone marrow-derived macrophages by suppressing caspase-1, IL-1β, and GSDMD cleavage, without altering the expression levels of core inflammasome components[1].
ODZ10117 (5-20 μM; 1 h pretreatment) does not inhibit AIM2 or NLRC4 inflammasome activation in LPS-primed mouse bone marrow-derived macrophages, demonstrating specificity for NLRP3 inflammasomes[1].
ODZ10117 (5-20 μM; 1 h pretreatment) dose-dependently inhibits NLRP3 inflammasome-mediated ASC translocation, oligomerization, and speck formation in LPS-primed mouse bone marrow-derived macrophages, without affecting ASC dynamics in AIM2 or NLRC4 inflammasome activation[1].
ODZ10117 (20 μM) inhibits the interaction between NLRP3 and NEK7 in HEK293T cells overexpressing these proteins[1].
ODZ10117 (300-900 μM; 30 min incubation with lysates) directly binds to NLRP3 and STAT3 in LPS-primed J774A.1 cell lysates, as shown by dose-dependent protection from pronase degradation, with no binding to NEK7 or caspase-1[1].
ODZ10117 binds to the ADP binding pocket of the NLRP3 NACHT domain via multiple stabilizing interactions, with a binding energy of -7.7 kcal/mol[1].
ODZ10117 snugly fits into the phospho-tyrosine binding pocket of the STAT3 SH2 domain with a Glide docking score of −6.17 kcal/mol, demonstrating higher binding affinity than known STAT3 inhibitors S3I-201 (HY-15146) and STA-21 (HY-121482)[2].
ODZ10117 (40 μM; 24 h) inhibits tyrosine phosphorylation of STAT3 in multiple constitutively STAT3-activated human cancer cell lines including HDLM-2, MDA-MB-231, HepG2, and U87MG[2].
ODZ10117 (40 μM; 24 h) inhibits IL-6-induced tyrosine phosphorylation of STAT3 in human cancer cell lines including RPMI8226, MCF-7, and U251MG[2].
ODZ10117 (40 μM; 24 h) inhibits STAT3 homodimerization and tyrosine phosphorylation in transfected MDA-MB-231 breast cancer cells[2].
ODZ10117 (40 μM; 24 h) induces apoptosis in MDA-MB-231 breast cancer cells by activating caspase-3 and PARP cleavage, and downregulating anti-apoptotic proteins Bcl-2, Bcl-xL, Mcl-1, and survivin[2].
ODZ10117 (40 μM; 24 h) inhibits nuclear translocation of tyrosine-phosphorylated STAT3 in MDA-MB-231 breast cancer cells[2].
ODZ10117 (2.5-40 μM; 24 h) inhibits STAT3 transcriptional activity in MDA-MB-231/STAT3-Luc breast cancer cells with an IC50 of 7.5 μM after 24 h of incubation[2].
ODZ10117 (40 μM; 0.5-12 h) inhibits tyrosine phosphorylation of STAT3 in MDA-MB-231 and MDA-MB-468 breast cancer cells starting at 2 h post-treatment[2].
ODZ10117 (10-40 μM; 9 h) inhibits tyrosine phosphorylation of STAT3 in MDA-MB-231 and MDA-MB-468 breast cancer cells in a concentration-dependent manner, with significant inhibition at ≥20 μM after 9 h of incubation[2].
ODZ10117 (40 μM; 16 h) specifically inhibits tyrosine phosphorylation of STAT3 without affecting other STAT family proteins, JAK kinases, or upstream signaling regulators Akt, Src, and ERK1/2 in MDA-MB-231 and MDA-MB-468 breast cancer cells[2].
ODZ10117 (10-100 μM; 24 h) reduces cell viability in MDA-MB-231, MDA-MB-468, ZR-75-1, and 4T1 breast cancer cells in a concentration-dependent manner after 24 h of incubation[2].
ODZ10117 (40 μM; 24 h) increases apoptotic cell death in MDA-MB-231 breast cancer cells, as shown by a five-fold increase in Annexin V-positive cells and a three-fold increase in PI-positive cells[2].
ODZ10117 (40 μM; 24 h) downregulates mRNA expression of STAT3-dependent anti-apoptotic genes Bcl-2, Bcl-xL, Mcl-1, and Survivin in MDA-MB-231 breast cancer cells[2].
ODZ10117 (40 μM; 24 h) reduces migration of MDA-MB-231 breast cancer cells in a wound healing assay[2].
ODZ10117 potently and selectively inhibits STAT3 transcriptional activity in breast cancer cells with an IC50 of 7.5 μM[3].
ODZ10117 exerts anticancer effects against MDA-MB-231 breast cancer cells by directly blocking the STAT3 SH2 domain, suppressing homodimerization and transcriptional activity, inducing apoptosis, and reducing migration and invasion[3].
ODZ10117 (10 μM; 12 h pretreatment) enhances cell viability in H2O2-treated SH-SY5Y human neuroblastoma cells by mitigating oxidative stress-induced cell damage[4].
ODZ10117 (10 μM; 12 h pretreatment) suppresses H2O2-induced caspase-dependent apoptosis in SH-SY5Y human neuroblastoma cells[4].
ODZ10117 (10 μM; 1-12 h) suppresses STAT3 phosphorylation and induces transient ERK and CREB phosphorylation in SH-SY5Y human neuroblastoma cells, with peak effects at 1 h[4].
ODZ10117 (10 μM; 1-12 h) upregulates protein expression of memory-associated IEGs and BDNF in SH-SY5Y human neuroblastoma cells, with detectable increases starting at 6 h[4].
ODZ10117 (10 μM; 3 h)-induced CREB phosphorylation in SH-SY5Y human neuroblastoma cells is dependent on ERK signaling[4].
ODZ10117 (10 μM; 3-6 h) upregulates mRNA expression of memory-associated IEGs in SH-SY5Y human neuroblastoma cells, with peak effects at 3 h[4].
ODZ10117 (10 μM; 12 h)-induced upregulation of memory-associated IEG and BDNF proteins in SH-SY5Y human neuroblastoma cells is dependent on ERK signaling[4].
ODZ10117 (10 μM; 12 h treatment) mitigates H2O2-induced oxidative stress and caspase-dependent apoptosis in SH-SY5Y human neuroblastoma cells is dependent on ERK signaling[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:mouse bone marrow-derived macrophages (BMDMs)
-
Concentration:5 μM; 10 μM; 20 μM; 40 μM
-
Incubation Time:6 h
-
Result:Showed no significant cytotoxicity on BMDMs at concentrations up to 40 μM, with cell viability remaining near 100% across all tested concentrations.
-
Cell Line:LPS-primed mouse bone marrow-derived macrophages (BMDMs)
-
Concentration:5 μM; 10 μM; 20 μM
-
Incubation Time:1 h pretreatment
-
Result:Dose-dependently inhibited the cleavage of pro-caspase-1 to active caspase-1 (p20), pro-IL-1β to active IL-1β (p17), and full-length GSDMD to N-terminal GSDMD (N-GSDMD) in cell supernatants and lysates.
Had no effect on the steady-state protein levels of NLRP3, ASC, pro-caspase-1, pro-IL-1β, or full-length GSDMD in cell lysates.
-
Cell Line:LPS-primed mouse bone marrow-derived macrophages (BMDMs)
-
Concentration:5 μM; 10 μM; 20 μM
-
Incubation Time:1 h pretreatment
-
Result:Dose-dependently suppressed ASC translocation to Triton X-100 insoluble fractions, ASC oligomerization, and ASC speck formation in BMDMs treated with NLRP3 triggers (ATP, nigericin, silica crystals).
Reduced ASC speck formation by ~50% for ATP and nigericin triggers at 20 μM.
Had no effect on ASC translocation or speck formation in BMDMs treated with AIM2 or NLRC4 triggers.
-
Cell Line:HDLM-2, L540, K562, KCL22, LAMA84, DU145, MDA-MB-231, MDA-MB-468, SKOV3, PANC-1, A549, NCI-H460, HCT116, SW620, MKN-45, A431, A375, SK-MEL-146, HepG2, Huh7, A172, U87MG, U373MG, SH-SY5Y
-
Concentration:40 μM
-
Incubation Time:24 h
-
Result:Reduced the level of tyrosine-phosphorylated STAT3 in all tested constitutively STAT3-activated human cancer cell lines, without altering total STAT3 levels.
-
Cell Line:RPMI8226, U266, U937, HL-60, HeLa, MCF-7, U251MG
-
Concentration:40 μM
-
Incubation Time:24 h
-
Result:Reduced the level of tyrosine-phosphorylated STAT3 induced by IL-6 stimulation in all tested human cancer cell lines, without altering total STAT3 levels.
-
Cell Line:MDA-MB-231 breast cancer cells
-
Concentration:40 μM
-
Incubation Time:24 h
-
Result:Decreased the level of tyrosine-phosphorylated STAT3 without altering total STAT3 levels, and significantly reduced STAT3 homodimerization compared to vehicle-treated cells.\nIncreased the levels of cleaved PARP and cleaved caspase-3, and reduced the protein levels of anti-apoptotic genes Bcl-2, Bcl-xL, Mcl-1, and Survivin compared to vehicle-treated cells.
-
Cell Line:MDA-MB-231 breast cancer cells
-
Concentration:40 μM
-
Incubation Time:24 h
-
Result:Reduced the nuclear accumulation of tyrosine-phosphorylated STAT3 compared to vehicle-treated cells, where phosphorylated STAT3 was prominently localized in the nucleus.
-
Cell Line:MDA-MB-231 and MDA-MB-468 breast cancer cells
-
Concentration:40 μM
-
Incubation Time:0.5 h; 1 h; 2 h; 4 h; 6 h; 9 h; 12 h
-
Result:Reduced tyrosine-phosphorylated STAT3 levels after 2 h of incubation, with the inhibitory effect sustained through 12 h of treatment, without altering total STAT3 levels.
-
Cell Line:MDA-MB-231 and MDA-MB-468 breast cancer cells
-
Concentration:10 μM; 20 μM; 30 μM; 40 μM
-
Incubation Time:9 h
-
Result:Reduced tyrosine-phosphorylated STAT3 levels in a concentration-dependent manner, with significant inhibition observed at concentrations ≥20 μM, without altering total STAT3 levels.
-
Cell Line:MDA-MB-231 and MDA-MB-468 breast cancer cells
-
Concentration:40 μM
-
Incubation Time:16 h
-
Result:Inhibited tyrosine phosphorylation of STAT3, but did not significantly affect phosphorylation levels of STAT1, STAT5, JAK1, JAK2, JAK3, Akt, Src, or ERK1/2, nor did it alter total levels of any of these proteins.
-
Cell Line:MDA-MB-231, MDA-MB-468, ZR-75-1, and 4T1 breast cancer cells
-
Concentration:10 μM; 20 μM; 40 μM; 60 μM; 80 μM; 100 μM
-
Incubation Time:24 h
-
Result:Decreased cell viability in a concentration-dependent manner across all tested breast cancer cell lines.
At 100 μM, cell survival was reduced to 30-50% of vehicle-treated controls.
-
Cell Line:MDA-MB-231 breast cancer cells
-
Concentration:40 μM
-
Incubation Time:24 h
-
Result:Increased the population of PI-positive dead cells from 7.86% to 26.7% and Annexin V-positive apoptotic cells from 3.13% to 15.3% compared to vehicle-treated cells.
-
Cell Line:MDA-MB-231 breast cancer cells
-
Concentration:40 μM
-
Incubation Time:24 h
-
Result:Reduced the mRNA levels of Bcl-2, Bcl-xL, Mcl-1, and Survivin to 20-40% of vehicle-treated control levels.
-
Cell Line:MDA-MB-231 breast cancer cells
-
Concentration:40 μM
-
Incubation Time:24 h
-
Result:Significantly reduced wound closure compared to vehicle-treated cells, indicating decreased cell migration.
-
Cell Line:human neuroblastoma SH-SY5Y cells
-
Concentration:10 μM
-
Incubation Time:12 h pretreatment
-
Result:Significantly increased cell viability in SH-SY5Y cells exposed to H2O2, reversing the ~50% reduction in viability caused by H2O2 alone (statistically significant compared to the H2O2-treated group, p<0.005).
-
Cell Line:human neuroblastoma SH-SY5Y cells
-
Concentration:10 μM
-
Incubation Time:12 h pretreatment
-
Result:Significantly reduced the total green object area (a measure of dead cell cytotoxicity) in SH-SY5Y cells exposed to H2O2, compared to the H2O2-only group (p<0.005).
-
Cell Line:human neuroblastoma SH-SY5Y cells
-
Concentration:10 μM
-
Incubation Time:12 h (pretreatment); 12 h (H2O2 exposure)
-
Result:Significantly reduced the percentage of Annexin V-positive apoptotic SH-SY5Y cells exposed to H2O2, compared to the H2O2-only group (p<0.005).
-
Cell Line:human neuroblastoma SH-SY5Y cells
-
Concentration:10 μM
-
Incubation Time:12 h pretreatment
-
Result:Reduced H2O2-induced cleavage of caspase-3, caspase-9, and PARP in SH-SY5Y cells, indicating inhibition of caspase-dependent apoptosis.
-
Cell Line:human neuroblastoma SH-SY5Y cells
-
Concentration:10 μM
-
Incubation Time:1 h; 3 h; 6 h; 12 h
-
Result:Induced peak p-STAT3 suppression at 1 h (persisting until 6 h), peak p-CREB levels at 1 h (gradually declining thereafter), and peak p-ERK levels at 1 or 3 h (gradually declining until 12 h) in SH-SY5Y cells.\nSignificantly increased protein levels of c-Fos, c-Jun, and BDNF in SH-SY5Y cells starting at 6 h.
-
Cell Line:human neuroblastoma SH-SY5Y cells
-
Concentration:10 μM
-
Incubation Time:3 h
-
Result:Pretreatment with PD98059 significantly reduced ODZ10117-induced p-ERK and p-CREB levels in SH-SY5Y cells.
-
Cell Line:human neuroblastoma SH-SY5Y cells
-
Concentration:10 μM
-
Incubation Time:3 h; 6 h
-
Result:Significantly increased mRNA levels of all tested immediate early genes (c-Fos, c-Jun, Arc, Egr-1, NR4A1, and Homer1a) in SH-SY5Y cells, with a more pronounced response observed at 3 h compared to 6 h.
-
Cell Line:human neuroblastoma SH-SY5Y cells
-
Concentration:10 μM
-
Incubation Time:12 h
-
Result:Induced increases in c-Fos, c-Jun, and BDNF protein levels in SH-SY5Y cells were abolished with PD98059 pretreatment.
-
Cell Line:human neuroblastoma SH-SY5Y cells
-
Concentration:10 μM
-
Incubation Time:12 h
-
Result:Reduction of cell viability was reversed in H2O2-treated SH-SY5Y cells with PD98059 pretreatment.
-
Cell Line:human neuroblastoma SH-SY5Y cells
-
Concentration:10 μM
-
Incubation Time:12 h
-
Result:Reduction in cytotoxicity, caspase-3, caspase-9, PARP cleavage and apoptotic cell rate was reversed in H2O2-treated SH-SY5Y cells with PD98059 pretreatment.
In Vivo
ODZ10117 (5-20 mg/kg; i.p.; two doses (12 h and 2 h prior to LPS)) dose-dependently reduces IL-1β release and improves survival rate in mice with LPS-induced sepsis, with significant efficacy observed at 10 and 20 mg/kg[1].
ODZ10117 (1-10 mg/kg; i.p.; 5 times per week; 23 days) suppresses orthotopic breast tumor growth in BALB/c nude mice in a dose-dependent manner, with the 10 mg/kg dose achieving greater tumor weight reduction than the 1 mg/kg dose[2].
ODZ10117 (10 mg/kg; intratumoral injection; every 2 days; 2 weeks) suppresses subcutaneous breast tumor growth in BALB/c nude mice and modulates STAT3-dependent apoptotic and metastatic markers in tumor tissue[2].
ODZ10117 (1-10 mg/kg; i.p.; 5 times per week; 3 weeks) suppresses primary tumor growth, reduces lung metastasis, and extends survival in a syngeneic breast cancer model in BALB/c mice, with the 10 mg/kg dose achieving greater efficacy than the 1 mg/kg dose[2].
ODZ10117 (10 mg/kg; intratumoral injection) significantly reduces tumor growth and lung metastasis in BALB/c mice with MDA-MB-231 breast cancer xenografts[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (female, 6-8 weeks old, intraperitoneal injection of MSU crystals at 50 mg/kg)[1]
-
Dosage:5 mg/kg; 10 mg/kg; 20 mg/kg
-
Administration:i.p.; single dose
-
Result:Suppressed MSU-induced IL-1β release in a dose-dependent manner.
Achieved statistically significant reductions in IL-1β levels at 10 mg/kg and 20 mg/kg (p < 0.01) compared to the MSU-only group.
-
Animal Model:C57BL/6 (female, 6-8 weeks old, intraperitoneal injection of LPS at 20 mg/kg)[1]
-
Dosage:5 mg/kg; 10 mg/kg; 20 mg/kg
-
Administration:i.p.; two doses (12 h and 2 h prior to LPS)
-
Result:Suppressed LPS-induced IL-1β release in a dose-dependent manner.
Achieved statistically significant reductions in IL-1β levels at 10 mg/kg and 20 mg/kg (p < 0.05) compared to the LPS-only group.
Improved survival rate: maintained 60% survival through 80 hours at 20 mg/kg, compared to 0% survival for the LPS-only group by 36 hours, with a statistically significant difference (p < 0.05).
-
Animal Model:BALB/c nude (6-week-old female, orthotopic xenograft via MDA-MB-231 cell injection into right fourth mammary fat pad)[2]
-
Dosage:1 mg/kg; 10 mg/kg
-
Administration:i.p.; 5 times per week; 23 days
-
Result:Reduced final tumor weight to ~1.8 g (1 mg/kg dose) compared to vehicle control ~2.4 g.
Suppressed tumor volume growth over 22 days (1 mg/kg dose).
Reduced final tumor weight to ~1.4 g (10 mg/kg dose).
Suppressed tumor volume growth to a greater degree than the 1 mg/kg dose (10 mg/kg dose).
Did not affect mouse body weight (both doses).
-
Animal Model:BALB/c nude (6-week-old female, subcutaneous xenograft via MDA-MB-231 cell injection into neck)[2]
-
Dosage:10 mg/kg
-
Administration:intratumoral injection; every 2 days; 2 weeks
-
Result:Significantly suppressed relative tumor volume growth over 14 days, with final relative volume ~2 compared to vehicle control ~5.
Reduced tumor cell population in treated tumors.
Decreased levels of pY705-STAT3, Bcl-xL, and pro-MMP-2 in treated tumors.
Increased levels of active caspase-3 in treated tumors.
-
Animal Model:BALB/c (6-week-old female, syngeneic xenograft via 4T1-Luc cell injection into right fourth mammary fat pad, spontaneous lung metastasis)[2]
-
Dosage:1 mg/kg; 10 mg/kg
-
Administration:i.p.; 5 times per week; 3 weeks
-
Result:Reduced primary tumor volume at 21 days (1 mg/kg dose).
Increased median mouse survival from 12 days to 20 days (1 mg/kg dose).
Reduced visible lung metastatic nodules to ~22 compared to vehicle control ~30 (1 mg/kg dose).
Reduced primary tumor volume to a greater degree than the 1 mg/kg dose (10 mg/kg dose).
Increased median survival to 21 days (10 mg/kg dose).
Reduced visible lung metastatic nodules to ~17 (10 mg/kg dose).
Did not affect mouse body weight (both doses).
-
Animal Model:BALB/c[3]
-
Dosage:10 mg/kg
-
Administration:intratumoral injection
-
Result:Significantly reduced tumor growth and lung metastasis.
Chemical Information
-
CAS No. 1632152-27-2
-
Molecular Weight 362.42
-
Formula C10H5Cl5N2O2
-
SMILES
ClC1=CC=C(C(Cl)=C1)OCC2=NOC(C(Cl)(Cl)Cl)=N2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Alzheimer’s Disease Modeling
Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by a progressive decline in cognitive functions and loss of specific types of neurons and synapses. Alzheimer's symptoms can be simulated in mice by injecting drugs (such as Aβ) or genetically modified.
-
Cytoplasmic-Nuclear Fractionated Protein Extraction
Cytoplasmic-nuclear fractionated protein extraction separates soluble cytoplasmic proteins from nuclear-enriched proteins by mild plasma-membrane permeabilization, differential centrifugation, washing of nuclei, and extraction of nuclear proteins for downstream immunoblotting or related molecular analysis. The readout is the relative abundance of a protein in cytoplasmic and nuclear fractions, commonly assessed by western blotting together with compartment markers such as tubulin or pyruvate kinase for cytoplasm and lamin, nucleoporin, hnRNP, H2AX, or Lamin B for nuclear fractions.
-
Dual Luciferin reporter gene assay
Luciferin reporter gene assay is a reporting system to detect the activity of Firefly Luciferase using luciferin as a substrate, which is often used in the research of miRNA target gene verification and promoter transcriptive activity regulation. Dual luciferase usually refers to Firefly luciferase and Renilla luciferase.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Chemotaxis Gradient Chamber Assay 1
The chemotaxis gradient chamber assay is based on the principle of observing directional cell migration in response to a stable, linear or quasi-linear concentration gradient of a chemoattractant formed between two fluid reservoirs separated by a narrow observation chamber. Cells placed within the chamber respond to the gradient by polarized movement toward higher chemoattractant concentrations, allowing quantification of chemotactic behavior in real time under microscopy. The classic Zigmond chamber design enables simultaneous visualization of gradient formation and individual cell trajectories, making it suitable for studying leukocyte chemotaxis and other motile cell types in vitro.
-
Under-Agarose Cell Migration Assay
The under-agarose cell migration assay is a classical in vitro chemotaxis method designed to evaluate directed cell movement through a semi-solid agarose matrix toward soluble chemoattractant gradients, enabling visualization and quantification of leukocyte or motile cell migration in a confined 2D-like environment. In this system, cells and chemoattractants are placed in separate wells cut into an agarose gel, allowing diffusion-driven gradient formation that guides directional migration, which is typically assessed by measuring migration distance, cell morphology changes, and accumulation toward the chemoattractant source. This assay has been widely used to study neutrophil and leukocyte chemotaxis as a simple alternative to filter-based migration systems and allows direct microscopic observation of migrating cells under near-physiological confinement conditions.
-
Transwell/Boyden Chamber Migration Assay
The Transwell/Boyden chamber migration assay measures cell movement through a porous membrane separating an upper and lower chamber, usually after a chemoattractant gradient is established by placing cells in the upper chamber and chemoattractant-containing medium in the lower chamber. The readout is generated by quantifying cells that traverse the membrane and appear on the lower membrane surface or in the lower chamber, depending on whether the cell type is adherent or non-adherent. This assay reflects chemotactic or haptotactic migration rather than matrix invasion unless an extracellular-matrix barrier is added to the membrane.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
3D Collagen/Hydrogel Matrix Migration Assay
The 3D collagen/hydrogel matrix migration assay is based on embedding cells within or on top of a fibrillar collagen type I-rich three-dimensional matrix to model in vivo-like extracellular matrix (ECM) architecture, enabling analysis of cell migration through a physically and biochemically relevant scaffold. In contrast to 2D migration systems, cells in 3D matrices interact with fibrillar collagen networks, requiring coordinated adhesion remodeling and proteolytic or non-proteolytic deformation mechanisms to move through confined spaces, thereby providing a more physiologically relevant readout of invasive and migratory behavior in tissue-like environments. Cell movement in 3D collagen matrices is typically quantified by tracking single-cell trajectories, invasion depth, or matrix penetration over time, reflecting combined effects of cytoskeletal dynamics, cell-ECM adhesion turnover, and ECM remodeling. These systems are widely used to study tumor cell invasion and stromal cell motili
-
Cell invasion
Cell invasion is the ability of cells to migrate from one area to another via the extracellular matrix. Cell invasion is the response of normal and cancer cells to chemical and mechanical stimuli. Before migrating to a new region, the extracellular matrix is degraded by proteases within the cell. Cell invasion often occurs during wound repair, vascularization and inflammation, abnormal tissue invasion, and tumor cell metastasis.
-
Cell-Exclusion Zone Migration Assay
The Cell-Exclusion Zone (CEZ) migration assay is an in vitro 2D cell migration method in which a defined cell-free area is created using removable physical barriers such as silicone stoppers, allowing cells to be seeded around the barrier and subsequently migrate into the cleared zone after barrier removal. This approach enables quantification of collective cell migration by monitoring repopulation of the initially cell-free region over time using microscopy-based imaging. Compared with scratch-based wound healing assays, barrier-based exclusion methods are designed to avoid mechanical damage to the extracellular matrix and reduce injury-induced effects on boundary cells, thereby improving interpretability of migration behavior in vitro. The assay readout is typically the progressive reduction in the cell-free area or the number of cells invading the exclusion zone, reflecting coordinated cell motility relevant to physiological processes such as wound healing, epithelial repair, and ca
-
Chemotaxis Gradient Chamber Assay 2
Chemotaxis gradient chamber assays measure directional cell migration in response to a soluble chemical gradient by imaging cells as they move across a defined observation region; the readout is generated from time-lapse cell trajectories, displacement toward the gradient, forward migration index, trajectory plots, rose/polar plots, and statistical tests of non-random directionality. The Dunn chamber is a direct-viewing glass chamber in which cells migrate across a bridge between control and chemoattractant wells, allowing observation of cells in a linear concentration gradient; related direct-viewing formats include the Insall chamber, which supports defined unidirectional gradients and high numerical-aperture microscopy, and the μ-Slide Chemotaxis chamber, which supports long-term live-cell imaging and gradient characterization with fluorescent dye.
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Scratch/Wound-Healing Migration Assay
The scratch/wound-healing migration assay measures collective migration of adherent cells into an experimentally created cell-free gap in a confluent monolayer. The readout is generated by imaging the gap immediately after scratching and at later time points, then quantifying reduction in wound area, wound width, or percentage closure as cells move into the denuded region. Gap closure reflects cell migration but may also include cell proliferation, so interpretation should distinguish migration-focused conditions from proliferation-driven closure when possible, such as by using short assay windows, serum-controlled conditions, cell counting, or proliferation controls reported in published protocols.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Neural Crest/Neuronal Cell Migration Explant Assay
Neural crest (NC) and neuronal cell migration explant assays are in vitro systems in which neural tube-derived tissues are cultured to allow premigratory or newly emigrated neural crest cells to undergo epithelial-to-mesenchymal transition (EMT), migrate away from the explant, and form a measurable radial outgrowth that reflects migratory capacity and environmental responsiveness. These assays typically quantify migration by measuring the expansion of cell outgrowth from neural tube or neural plate border explants over time, often comparing early and later timepoints to derive a migration index such as a radius ratio, which reflects net cell dispersal from the explant core. Neural tube explant cultures preserve key aspects of neural crest behavior, including EMT, migration, and early differentiation, making them suitable for assessing intrinsic migratory ability and extrinsic cue dependence. However, studies emphasize that migratory outgrowth from neural tube explants may include non-n
-
Zymosan-Induced Peritonitis
Zymosan-induced peritonitis is a sterile acute-inflammation model produced by intraperitoneal injection of zymosan, a yeast cell-wall particle preparation, followed by quantification of leukocyte recruitment and soluble inflammatory mediators in peritoneal lavage fluid. Low-dose zymosan peritonitis is commonly used as a self-resolving acute inflammation model in which neutrophil recruitment occurs early and monocyte/macrophage accumulation follows later. The assay readouts include total peritoneal leukocyte number, differential neutrophil and monocyte/macrophage counts, peritoneal cytokines and chemokines, plasma or peritoneal exudation, and optional lipidomic or metabolomic changes during inflammation and resolution. Early neutrophil recruitment after zymosan depends strongly on complement and mast-cell C5a receptor signaling, whereas later monocyte recruitment is linked to MCP-1/CCL2 production.
-
Patient-Derived Orthotopic Xenograft (PDOX)
Patient-derived orthotopic xenograft (PDOX) modeling implants fresh patient tumor tissue or patient-derived tumor cells into the anatomically corresponding organ or tissue site of immunodeficient mice, usually by surgical orthotopic implantation, to preserve patient tumor histology, local microenvironmental context, invasion, metastatic behavior, and treatment-response features better than subcutaneous implantation. PDOX readouts include tumor engraftment, orthotopic tumor growth, local invasion, metastasis, recurrence after resection, histologic similarity to the donor tumor, biomarker retention, molecular concordance, survival, and response or resistance to therapy. PDOX models are used for preclinical drug testing and individualized therapy evaluation, but engraftment success varies by tumor type and specimen quality.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
LPS-Induced Endotoxemia/Systemic Inflammation
Lipopolysaccharide (LPS)-induced endotoxemia is a widely used in vivo model of acute systemic inflammation in which LPS, a Gram-negative bacterial endotoxin, activates innate immune signaling primarily through TLR4, leading to rapid and transient induction of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in circulation and tissues. This cytokine surge is commonly used as a measurable readout of systemic inflammatory activation and immune dysregulation, and is typically assessed within hours after intraperitoneal LPS administration in mouse models of endotoxemia. The model captures key features of systemic inflammatory response syndrome, including cytokine release, immune cell activation, and downstream tissue responses, and has been used to evaluate anti-inflammatory interventions such as cytokine modulation, lipid mediators, and immune cell-targeting therapies.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Tail-Vein Experimental Metastasis Xenograft
Tail-vein experimental metastasis xenograft models assess the ability of injected tumor cells to survive circulation, arrest in vascular beds, extravasate, and colonize distant organs, most commonly lung after lateral tail-vein injection; this model bypasses primary-tumor formation, local invasion, and intravasation, so the readout reflects late metastatic colonization rather than the full metastatic cascade. The main readouts are metastatic burden measured by bioluminescence imaging, gross metastatic nodules, histology, organ weight, survival, or ex vivo tumor-cell quantification; luciferase-labeled tumor cells permit longitudinal noninvasive monitoring, while histology confirms organ colonization and tissue localization.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
Purity & Documentation
References
[1]. Kang JH, et al. Novel Activity of ODZ10117, a STAT3 Inhibitor, for Regulation of NLRP3 Inflammasome Activation. Int J Mol Sci. 2023;24(7):6079. Published 2023 Mar 23. [Content Brief]
[2]. Kim BH, et al. Development of Oxadiazole-Based ODZ10117 as a Small-Molecule Inhibitor of STAT3 for Targeted Cancer Therapy. J Clin Med. 2019;8(11):1847. Published 2019 Nov 2. [Content Brief]
[3]. Dong J, et al. Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation. J Med Chem. 2021;64(13):8884-8915. [Content Brief]
[4]. Kim SK, et al. Neuroprotective Effects of STAT3 Inhibitor on Hydrogen Peroxide-Induced Neuronal Cell Death via the ERK/CREB Signaling Pathway. Neurochem Res. 2024;50(1):52. Published 2024 Dec 9. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)